FDA said it intends to respond soon to citizen petitions related to CBD, and statements from the agency suggest it may look to Congress for a solution on regulating the hemp-based compound in food and dietary supplements.
“Given what we know about the safety of CBD so far, it raises concerns for FDA about whether these existing regulatory pathways for food and dietary supplements are appropriate for this substance,” the Wall Street Journal quoted FDA Principal Deputy Commissioner Janet Woodcock in a Dec. 29 article.
FDA also provided a quote to the paper, which was attributable to Woodcock, that the agency was reviewing three CBD-related citizen petitions and intended “to respond to them soon,” according to an FDA spokesperson in an email.
The Journal did not explicitly mention the citizen petitions. However, citing agency officials, the newspaper reported FDA “is studying whether legal cannabis is safe in food or supplements and plans to make recommendations for how to regulate the growing number of cannabis-derived products in the coming months.”
Over a four-year period, three trade organizations representating stakeholders in the dietary supplement industry filed citizen petitions with FDA regarding CBD: the Council for Responsible Nutrition (CRN); Consumer Healthcare Products Association (CHPA); and the Natural Products…